I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
If you are not a healthcare professional and you want to learn about contraception please click below.
If you are not a healthcare professional and you want to learn about heavy menstural bleedingplease click below.
HCP

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

DHSC: Prevention green paper open for consultation

06 November 2019

On 22 July 2019, the Department for Health and Social Care (DHSC) published the prevention green paper, setting out proposals for the future direction of a prevention strategy.

The paper – Advancing our health: Prevention in the 2020s – was published directly before former Prime Minister Theresa May’s departure from No.10 and without the blessing of Secretary of State for Health and Social Care, Matt Hancock.

With regards to women’s health, the green paper emphasises the important role of local authorities, acknowledging that there have been good examples of ‘creative and energetic’ commissioning. It maintains the important role of local authorities and steers them towards a more joined-up way of working with the NHS, as based on existing best practices from across the country. Here, Integrated Care Systems (ICS) are showcased as a good opportunity for improving integration and serving as a natural way forward for commissioning in sexual and reproductive health.

While the paper did not explicitly discuss women’s reproductive rights or menstrual health policy, it did suggest that it may be time for a new strategy, as previously called for by Westminster’s Health and Social Care Committee.

This paper is complimented by the recent publication of 6 LGA case studies - Sexual health commissioning in local government, which highlights six areas around the country where collaborative commissioning has been successful. Among these, all but one (Cheshire and Merseyside) had some focus on LARC and HMB, including Teesside, Lambeth, Southwark and Lewisham, Gloucestershire, Leicester, Leicestershire and Rutland, and Plymouth.

The emphasis on solutions should provide opportunities for renewed engagement on LARC uptake with our stakeholders and supports the access and new models of care strategy.

Recommendations

Online learning

Read more

Upcoming webinars

Read more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0278 November 2019

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Tue, 06/02/2020 - 05:21

Bayer logo